Improving the Investment Case for R&D in Neglected Infectious Diseases
Event
3/22/16
Neglected diseases continue to affect over a billion people worldwide and effective treatments and diagnostics are scarce. Yet research and development (R&D) for products to prevent and treat these diseases tend to be underfunded. A major barrier, particularly for pharmaceutical companies, is a lack of economic incentives to justify R&D. So how can we make the investment case and incentives for industry engagement stronger?
